Servicio de Hematología, Hospital Universitario Vall d'Hebron-Universitat Autónoma de Barcelona, Barcelona, España.
Unidad de Trasplante de Progenitores Hematopoyéticos Pediátrica, Hospital Universitari Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España.
Med Clin (Barc). 2019 Jul 5;153(1):28-34. doi: 10.1016/j.medcli.2019.01.017. Epub 2019 Mar 8.
Immunotherapy is changing the treatment of acute lymphoblastic leukaemia (ALL) in adults and children. However, regardless of these new therapies, allogeneic hematopoietic cell transplantation (allo-HCT) still play a key role in the treatment of ALL, although it is uncertain how these new therapies will impact on the transplant procedure and indications. This article reviews the indications of allo-HCT for children and adults diagnosed with ALL, the different sources and conditioning regimens for transplantation as well as the role of measurable residual diseases pre- and post-HCT in the era of the new therapies for ALL.
免疫疗法正在改变成人和儿童急性淋巴细胞白血病（ALL）的治疗方法。然而，无论这些新疗法如何，异基因造血细胞移植（allo-HCT）在 ALL 的治疗中仍然起着关键作用，尽管尚不确定这些新疗法将如何影响移植程序和适应症。本文综述了诊断为 ALL 的儿童和成人进行 allo-HCT 的适应症、移植的不同来源和预处理方案，以及在 ALL 的新疗法时代，移植前后可测量残留疾病的作用。
